Background Conflicting data exist with regard to recurrence rates of intestinal metaplasia
(IM) and dysplasia after achieving complete eradication of intestinal metaplasia (CE-IM) in …

Background & Aims There have been few studies describing the long-term durability of
complete eradication of intestinal metaplasia (CE-IM) in patients with Barrett's esophagus …

Background and Aims Previous estimates of incidence of intestinal metaplasia (IM)
recurrence after achieving complete remission of IM (CRIM) through endoscopic therapy of …

Background and Aims Endoscopic eradication therapy (EET) is the main treatment for
dysplastic Barrett's esophagus and intramucosal adenocarcinoma. Although the goal of EET …

Background & Aims The goal of treatment for Barrett's esophagus (BE) with dysplasia is
complete eradication of intestinal metaplasia (CEIM). The long-term durability of CEIM has …

Background and Aims Surveillance endoscopy is recommended after endoscopic
eradication therapy (EET) for Barrett's esophagus (BE) because of the risk of recurrence …

BACKGROUND: Endoscopic eradication therapy (EET) is highly effective in treating
dysplastic Barrett's esophagus (BE). Current surveillance intervals after complete remission …

Objectives: Recent data suggest that effective control of gastroesophageal reflux improves
outcomes associated with endoscopic eradication therapy (EET) for Barrett's esophagus …

Objective Surveillance interval protocols after complete remission of intestinal metaplasia
(CRIM) post radiofrequency ablation (RFA) in Barrett's oesophagus (BE) are currently …

BACKGROUND & AIMS: Radiofrequency ablation (RFA) is an established treatment for
dysplastic Barrett's esophagus (BE). Although short-term end points of ablation have been …